Although recent drugs including biological agents and small molecules targeting key inflammatory mediators have revolutionized the management of different chronic inflammatory diseases, these treatments lead to the development of psoriasis-like skin lesions in 2-5% of treated patients called paradoxical psoriasis. ¹ Here we report the first case of paradoxical psoriasis induced by baricitinib, a novel janus kinase (JAK) 1/2 inhibitor.